Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953334 | 0.86 | CHRM2 (0.43) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL955915 | 0.86 | NISCH (0.47) | NISCHADRA2AADRA2BADRA2CF2RL1 | |
| SCHEMBL10956049 | 0.85 | HRH1 (0.56) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL954931 | 0.85 | F2RL1 (0.46) | ADRA2AADRA2BADRA2CF2RL1 | |
| SCHEMBL955399 | 0.85 | ADRA2B (0.47) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL11229432 | 0.83 | CHRM2 (0.63) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL954387 | 0.83 | TAAR1 (0.43) | SLC6A2SLC6A4ADRA2AADRA2BADRA2C | |
| SCHEMBL955398 | 0.83 | FPR2 (0.41) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL954849 | 0.83 | F2RL1 (0.45) | ADRA2AADRA2BADRA2CF2RL1 | |
| Hydrochloric Acid SCHEMBL29248987 | 0.83 | TXN (0.42) | MTORADKNISCHADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118369306-A | Enol ether pro-fragrances | 弗门尼舍有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1928992-A1 | CONSUMER PRODUCTS HAVING VARYING ODORS | Henkel AG & Co. KGaA (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1920042-A1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007128326-A1 | PERFUME DELIVERY SYSTEM FOR CLEANERS | EVONIK GOLDSCHMIDT GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007028478-A1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028479-A1 | CONSUMER PRODUCTS HAVING VARYING ODORS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | CHRM2 191/4885SLC6A2 63/4885SLC6A4 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.